Contact
Please use this form to send email to PR contact of this press release:
Algernon Announces Enrollment of First U.S. Patient in Multinational Phase 2b/3 Human Study of Ifenprodil for Treatment of COVID-19
TO:
Please use this form to send email to PR contact of this press release:
Algernon Announces Enrollment of First U.S. Patient in Multinational Phase 2b/3 Human Study of Ifenprodil for Treatment of COVID-19
TO: